JNJ
190.6
-0.77%↓
ABT
126.77
+0.33%↑
MDT
93.77
-0.45%↓
VEEV
293.21
+0.68%↑
A
148.21
+0.39%↑
JNJ
190.6
-0.77%↓
ABT
126.77
+0.33%↑
MDT
93.77
-0.45%↓
VEEV
293.21
+0.68%↑
A
148.21
+0.39%↑
JNJ
190.6
-0.77%↓
ABT
126.77
+0.33%↑
MDT
93.77
-0.45%↓
VEEV
293.21
+0.68%↑
A
148.21
+0.39%↑
JNJ
190.6
-0.77%↓
ABT
126.77
+0.33%↑
MDT
93.77
-0.45%↓
VEEV
293.21
+0.68%↑
A
148.21
+0.39%↑
JNJ
190.6
-0.77%↓
ABT
126.77
+0.33%↑
MDT
93.77
-0.45%↓
VEEV
293.21
+0.68%↑
A
148.21
+0.39%↑
24h
Current
Min
8
Max
8.16
Income | 26M -26M |
|---|---|
Sales | 2.1M 2.1M |
Profit margin | -1,213.57 |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +90.82% upside |
Next Earnings | 4 Nov 2025 |
|---|
Market Cap | 377M |
|---|---|
Previous open | 5.44 |
Previous close | 8 |
Past performance is not a reliable indicator of future results.
8 May 2025, 19:14 UTC
Verastem Ovarian-Cancer Drug Combination Gets FDA Approval -- Update
DJ
Read
31 Dec 2024, 19:15 UTC
Verastem Shares Soar on FDA Priority Review of Cancer Treatment
DJ
Read
Price change
By TipRanks
12 Months Forecast
Average 15.17 USD 90.82%
High 20 USD
Low 13 USD
Based on 7 Wall Street analysts offering 12 month price targets forVerastem Inc - Dist in the last 3 months.
By TipRanks
Strong Buy
7 ratings
7
Buy
0
Hold
0
Sell
Based on 7 analysts giving stock ratings to Verastem Inc - Dist in the past 3 months.
Selling and administration expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$